In recent years, single-use polyvinyl chloride (PVC) endotracheal tubes (ETTs) have been almost universally accepted in the practice of anaesthesia and intensive care medicine. Despite their widespread employment, few who utilise these tubes on a day-to-day basis have ever considered their evolution 1 .
In 1928, Ivan Magill described the technique of inhalational anaesthesia using a single wide-bore, rubber ETT 2 . Through a process of trial and error, Magill had discovered that lengths of tubing originally intended to carry household natural gas were ideal for this purpose and obtained his initial supplies from an old rubber shop on London's Tottenham Court Road 3 . After the shop was destroyed by a German bomb, he sought the assistance of Charles King in providing a steady supply of mineralised rubber tubes of suitable shape and consistency.
Within a decade of Magill's paper, specialised rubber ETTs were being commercially manufactured and inhalational anaesthesia had almost entirely replaced the use of insufflation 5 for major maxillofacial surgery. Throughout the Second World War, ETTs were used 'without exception' 6 in patients repatriated to specialised maxillofacial hospitals in the United Kingdom. Additionally, they were commonly employed in a number of mobile maxillofacial surgical units which had been set up to manage such injuries in the theatre of war. One such outfit, stationed in North Africa and Italy between 1942 and 1944, performed more than 1000 operations on allied servicemen with severe injuries to the face and jaw 7 . Reusable rubber Magill tubes were utilised in more than 85% of cases.
Despite their widespread use, mineralised rubber ETTs exhibited various shortcomings. The mineralisation process involved the addition of a variety of compounds, including magnesium, cadmium, lead, barium and calcium. These chemicals served to alter the speed of vulcanisation, but left residues which, in some cases, could lead to tissue irritation. Rubber ETTs could also kink and obstruct if acutely flexed, were prone to degradation by certain lubricants, antiseptics, and anaesthetic agents, and quickly deteriorated when they were sterilised in boiling water 8, 9 . Mineralised rubber became more rigid with increases in temperature 10 . Furthermore, natural rubber was in short supply during the war. When ETTs made from synthetic rubber were found to possess too thick a wall to make them practical 9 , it occurred to Major Harold Thornton, a Royal Army Medical Corps anaesthetist working in a maxillofacial unit in Basingstoke, that materials such as vinyl acrylic resins and co-polymers might be worthy of investigation 8 . In 1943, Thornton discussed this idea with Sidney Leader, a dentist, entrepreneur and founder of Portland Plastics Ltd (later Portex).
Within a year, Leader supplied samples of 'Vinyl-Portex' tubing to Thornton and Majors Gordon and Ainslie of the Royal Canadian Army Medical Corps, who were also stationed in Basingstoke. When new, these tubes appeared white and semi-translucent and, although they became increasingly yellow and opaque, could be boiled hundreds of times and still remain serviceable. If a cuff was required, a rubber latex one was tied on 11 . Vinyl-Portex ETTs were unaffected by substances which were known to degrade rubber. They also softened and moulded to the contours of the airway as they warmed to body temperature and seemed less prone to kinking than their rubber counterparts 8,9 . Thornton was subsequently deployed with a mobile maxillofacial surgical unit stationed in France and Belgium after the D-day landings. Using Vinyl-Portex tubes for many of the 1687 anaesthetics administered in this unit, he re-confirmed these benefits and was able to report that PVC ETTs appeared non-irritant, even when utilised for prolonged procedures 12 .
Following their successful use by military anaesthetists during the Second World War, Vinyl-Portex tubes were manufactured in a variety of sizes and made available to civilian anaesthetists. These were found to be satisfactory for use in adults and children undergoing procedures in a busy neurosurgical centre in the UK in 1945 13 , and were utilised in almost 4000 paediatric intubations performed at The Children's Memorial Hospital in Montreal between 1951 and 1953 14 .
Around the same time, an American entrepreneur named David Sheridan established his own company producing plastic extruded catheters in a converted barn on his property in Argyle, New York 1 . After some experimentation, the Sheridan Catheter and Instrument Corporation began producing reusable opaque PVC ETTs, which were marketed through a variety of companies 15, 16 .
Further developments in chemical technology and extrusion
The evolution of the polyvinyl chloride endotracheal tube allowed the addition of an integral PVC cuff by 1958 17 , and later, the addition of radio-opaque markers and air-lines within the annulus of the tube. The latter was never possible with extruded rubber 10 .
In 1962, Bernard Brandstater of the American University Hospital, Beirut, was the first to report the successful use of PVC tubes for long-term intubation in infants and children ranging in age from newborn to four years 18 . Soon after, further positive case reports emerged from children's hospitals in Adelaide 19 , Melbourne 20 and Liverpool 21 . While longterm intubation of a handful of comatose adults had been described during the late 1940s and early 1950s [22] [23] [24] , these paediatric case reports rekindled interest in this practice 25 . However, as the incidence of prolonged intubation increased during the late 1960s, so too did concerns about mucosal damage secondary to leaching of toxic substances used in the manufacture of PVC 26 .
In 1968, Wallace Guess and John Stetson published the results of experiments in which slivers of PVC ETTs were found to produce toxic reactions when implanted in rabbit muscle 27 . Their report concluded that national standards should be established for the composition and testing of plastic ETTs and, as a result, a group from Sectional Committee Z79 of the American National Standards Institute was formed to address the issue. Following consultation with representatives from industry, government and healthcare, it was ruled that all PVC ETTs must be non-toxic and free from tissue reaction when implant tested. Tubes that satisfied these requirements could be marked Z79-IT. Around the same time, concerns were raised that sterilisation of PVC tubes using ethylene oxide could produce ethylene chlorohydrin 28 . This toxic substance could be released from PVC tubing long after sterilisation, causing erythema and tissue oedema. As a result, the first calls were made for PVC ETTs to be single-use 28 .
In 1975, Wallace Ring, John Adair and Richard Elwyn, from Salt Lake City, described a new design of preformed ETT 29 . This was specifically patented to be made from PVC or other thermoplastic materials 30 . Two years later, trials began with the first PVC double-lumen tube 31 .
Despite these advances, reusable rubber ETTs remained in widespread use until the late 1980s when the reuse of invasive medical equipment became increasingly unacceptable. P. J. Featherstone, C. M. Ball, R. N. Westhorpe Melbourne, Victoria
